白细胞介素-6在肝癌发生、发展及预后中的作用

国际肿瘤学杂志››2017,Vol. 44››Issue (10): 787-789.doi:10.3760/cma.j.issn.1673-422X.2017.10.016

白细胞介素-6在肝癌发生、发展及预后中的作用

张斌,史冬梅,乔森

250062 济南大学 betway.com 医学与生命科学学院（张斌）；山东省济宁市第一人民医院皮肤科（史冬梅），肝胆外科（乔森）

出版日期:2017-10-08发布日期:2017-11-08
通讯作者:乔森 E-mail:qsenqiao@sina.com
基金资助:
国家自然科学基金（81401653）；山东省自然科学基金（ZR2015HL127）

Roles of interleukin6 in occurrence, development and prognosis of hepatocellular carcinoma

Zhang Bin, Shi Dongmei, Qiao Sen

School of Medicine and Life Sciences, University of Ji′nan University and Shandong Academy of Medical Sciences, Ji′nan 250062, China

Online:2017-10-08Published:2017-11-08
Contact:Qiao Sen E-mail:qsenqiao@sina.com
Supported by:
National Natural Science Foundation of China (81401653); Natural Science Foundation of Shandong Province of China (ZR2015HL127)

摘要/Abstract

摘要：白细胞介素6（IL6）参与体内多种炎症反应和免疫调节等过程，并与肿瘤进程关系密切。近期研究发现，IL6通过参与肝癌微环境构成、激活相关通路、调控下游转录因子等影响肿瘤细胞增殖、侵袭和转移，在肝癌靶向治疗中具有重要潜在价值。

张斌,史冬梅,乔森. 白细胞介素-6在肝癌发生、发展及预后中的作用[J]. 国际肿瘤学杂志, 2017, 44(10): 787-789.

Zhang Bin, Shi Dongmei, Qiao Sen. Roles of interleukin6 in occurrence, development and prognosis of hepatocellular carcinoma[J]. Journal of International Oncology, 2017, 44(10): 787-789.

［1］ Gravitz L. liver cancer［J］. Nature, 2014, 516(7529): S1. DOI: 10.1038/516S1a. ［2］ Hirano T. Revisiting the 1986 molecular cloning of interleukin 6［J］. Front Immunol, 2014, 5: 456. DOI: 10.3389/fimmu.2014.00456. ［3］ He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autorine IL6 signaling［J］. Cell, 2013, 155(2): 384396. DOI: 10.1016/j.cell.2013.09.031. ［4］ Tian G, Mi J, Wei X, et al. Circulating interleukin6 and cancer: a metaanalysis using Mendelian randomization［J］. Sci Rep, 2015, 5: 11394. DOI: 10.1038/srep11394. ［5］ Zhu CP, Wang AQ, Zhang HH, et al. Research progress and prospects of markers for liver cancer stem cells［J］. World J Gastroenterol, 2015, 21(42): 1219012196. DOI: 10.3748/wjg.v21.i42.12190. ［6］吴林, 宦宏波, 吴黎雳, 等. 炎症因子与肝癌干细胞标志在肝癌诱导过程中的相关性研究［J］. 实用临床医药杂志, 2014, 18(7): 16. DOI: 10.7619/jcmp.201407001. ［7］ Piperi C, Samaras V, Levidou G, et al. Prognostic significance of IL8STAT3 pathway in astrocytomas: correlation with IL6, VEGF and microvessel morphometry［J］. Cytokine, 2011, 55(3): 387395. DOI: 10.1016/j.cyto.2011.05.012. ［8］ Matsumura A, Kubota T, Taiyoh H, et al. HGF regulates VEGF expression via the cMet receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells［J］. Int J Oncol, 2013, 42(2): 535542. DOI: 10.3892/ijo.2012.1728. ［9］ Stahl A, Joyal JS, Chen J, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis［J］. Blood, 2012, 120(14): 29252929. DOI: 10.1182/blood201204422527. ［10］ Rhee YH, Jeong SJ, Lee HJ, et al. Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells［J］. BMC Cancer, 2012, 12: 28. DOI: 10.1186/147124071228. ［11］ Zhao XL, Sun T, Che N, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelialmesenchymal transition regulator Twist1［J］. J Cell Mol Med, 2011, 15(3): 691700. DOI: 10.1111/j.15824934.2010.01052.x. ［12］ Cho KH, Jeong KJ, Shin SC, et al. STAT3 mediates TGFβ1induced TWIST1 expression and prostate cancer invasion［J］. Cancer Lett, 2013, 336(1): 167173. DOI: 10.1016/j.canlet.2013.04.024. ［13］ Yang L, Hou Y, Yuan J, et al. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways［J］. Oncotarget, 2015, 6(28): 2575525769. DOI: 10.18632/oncotarget.4697. ［14］ So KA, Min KJ, Hong JH, et al. Interleukin6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelialmesenchymal transition［J］. Int J Oncol, 2015, 47(4): 14511459. DOI: 10.3892/ijo.2015.3122. ［15］ Wang CQ, Sun HT, Gao XM, et al. Interleukin6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via upregulating osteopontin expression［J］. Am J Cancer Res, 2016, 6(9): 18731889. ［16］ Ghaffari A, Hoskin V, Szeto A, et al. A novel role for ezrin in breast cancer angio/lymphangiogenesis［J］. Breast Cancer Res, 2014, 16(5): 438. DOI: 10.1186/s1305801404382. ［17］张斌, 钟德玝, 王群伟, 等. JAK/STAT信号通路与肝细胞性肝癌的肿瘤进展和预后的相关性研究［J］. 细胞与分子免疫学杂志, 2010, 26(4): 368373. DOI: 10.13423/j.cnki.cjcmi.005452. ［18］ Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2012, 379(9822): 12451255. ［19］ Zhao WC, Fan LF, Yang N, et al. Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma［J］. Eur J Surg Oncol, 2013, 39(8): 858864. DOI: 10.1016/j.ejso.2013.04.003. ［20］ Sheng T, Wang B, Wang SY, et al. The relationship between serum interleukin6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection［J］. Medicine (Baltimore), 2015, 94(24): e941. DOI: 10.1097/MD.0000000000000941. ［21］ Ghoshal S, Fuchs BC, Tanabe KK, et al. STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC［J］. Hepatobiliary Surg Nutr, 2016, 5(3): 201203. DOI: 10.21037/hbsn.2016.03.02. ［22］ Hur W, Ryu JY, Kim HU, et al. Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133［J］. Sci Rep, 2017, 7: 45557. DOI: 10.1038/srep45557. ［23］ Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population［J］. Mol Cell, 2012, 47(4): 570584. DOI: 10.1016/j.molcel.2012.06.014. ［24］ Martin del Campo SE, Levine KM, MundyBosse BL, et al. The Raf kinase inhibitor sorafenib inhibits JAKSTAT signal transduction in human immune cells［J］. J Immunol, 2015, 195(5): 19952005. DOI: 10.4049/jimmunol.1400084.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[13]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[14]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[15]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.